NASDAQ | ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions.
The fund generally is expected to consist of more than 15 companies but not more than 100 companies.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 9.71% |
| RHHBY | Roche Holding Ltd ADR | Healthcare | Drug Manufacturers - General | 5.50% |
| JNJ | Johnson & Johnson | Healthcare | Drug Manufacturers - General | 4.79% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 4.78% |
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 4.23% |
| TMO | Thermo Fisher Scientific Inc | Healthcare | Diagnostics & Research | 3.86% |
| UNH | UnitedHealth Group Incorporated | Healthcare | Healthcare Plans | 3.84% |
| GILD | Gilead Sciences Inc | Healthcare | Drug Manufacturers - General | 3.72% |
| NOVN | Novartis AG | Healthcare | Drug Manufacturers - General | 3.51% |
| NOVO-B | Novo Nordisk A/S | Healthcare | Drug Manufacturers - General | 3.49% |
| ABT | Abbott Laboratories | Healthcare | Medical Devices | 3.28% |
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 3.11% |
| DHR | Danaher Corporation | Healthcare | Diagnostics & Research | 2.93% |
| ABBV | AbbVie Inc | Healthcare | Drug Manufacturers - General | 2.89% |
| 0QIU | Novo Nordisk A/S Class B | 2.74% | ||
| BSX | Boston Scientific Corp | Healthcare | Medical Devices | 2.42% |
| MDT | Medtronic PLC | Healthcare | Medical Devices | 2.37% |
| BBIO | BridgeBio Pharma Inc | Healthcare | Biotechnology | 2.31% |
| RVMD | Revolution Medicines Inc | Healthcare | Biotechnology | 2.23% |
| BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 2.13% |